WuXi Biologics, a leading global open-access biologics technology platform company, offering end-to-end solutions for biologics discovery, development and manufacturing, is planning to build an integrated biologics development, clinical and commercial manufacturing centre in the city of Shijiazhuang, capital of Hebei province in northern China.

The new facility of $240 million is an addition to WuXi Biologics' existing CDMO facilities in Shanghai and a $392 million biologics CDMO facility in Ireland, announced last month.

The new state-of-the-art biologics centre will include process development labs, clinical manufacturing facility (MFG9) with 5,000 L bioreactor capacity and commercial manufacturing facility (MFG8) with 48,000 L bioreactor capacity which will be built to meet cGMP standards of the United States, the European Union, and China. Besides serving global clients, the new integrated centre will also support Marketing Authorization Holder (MAH) system in China and address urgent needs of Chinese partners. Initial phase of the center will be operational in 2020.